Weighing The Evidence: Direct Oral Anticoagulant Use In Obese Patients

Weighing the Evidence: Direct Oral Anticoagulant Use in Obese Patients

ATRIUM Collaborative

Managing Anticoagulated Patients with Obesity: Focus on Direct Oral Anticoagulants Program

NAThrombosisForum

Direct oral anticoagulation therapy for VTE at extremes of body weight

Obesity and Anticoagulation - Case Study

ThrombosisCanada

The use of direct oral anticoagulants & low molecular weight heparins with cancer patients

RTI Health Solutions

DOACs in Elderly Patients and Extremes of Weight

ThrombosisCanada

Weighing the Evidence: A Pharmacy Approach to Stroke Prevention in Obese Patients with NVAF

ASH Highlights 2016 – Safety of Direct Oral Anticoagulants in Patients of Extreme Weight

Weighing the Evidence: A Pharmacy Approach to Stroke Prevention in Obese Patients with Non-Valvular

Apixaban vs. Warfarin in the treatment of venous thromboembolism in morbidly obese patients

Self Regional Healthcare

Clot Chronicles: DOACs and Obesity

NAThrombosisForum

The Blessing and Curse of Direct Oral Anticoagulants in the Bleeding Patient

NAThrombosisForum

Clot Chronicles: Updated Guidance on Managing Bleeding in Patients on Oral Anticoagulation

NAThrombosisForum

Obesity Paradox in Heart Failure: Weighing the Evidence

Managing Bleeding Events in Patients Receiving Direct Oral Anticoagulants

Evidence-Based Optimized Dosing Guidance in the Morbidly Obese Patient

International Anesthesia Research Society

The role of the pharmacist in Direct Oral Anticoagulant (DOAC) management 2020

Direct Oral Anticoagulant Drugs

Medical Masterclass Spring

NOAC vs Warfarin, Current Status of Venous Anticoagulation (Baltazar MD; Petkova MD) March 24, 2021

Houston Methodist DeBakey CV Education

Direct Oral Anticoagulants (DOACs) and the impact of 'antidotes' - CardioEd Lecture